Neorx
Manufacturing · Washington, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
300 Elliott Ave W Ste 500, Seattle, Wash...Phone Number
(206) 281-7001Website
www.neorx.comRevenue
$7.3 MillionIndustry
ZI Rank: 1
About Neorx
Neorx Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Neorx your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check out if Neorx is spiking on competitors!
Congratulate Masked Content for being promoted to Masked Content at Neorx
Neorx, which may be a good buyer, showed buying intent in Masked Content Topic
Check if Neorx has recently received funding, and reach out quickly before it becomes old news!
Earning: See what the market has to say on Neorx recently announced quarterly report
Website visits: Recent activity has been detected on your website
Click to see if Neorx had a recent Job posting/layoffs
Product Launch: Get notified when Neorx launches new products
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Funding: Get notified immidiatlly once Neorx has new funding data
Recommended Actions
Reach out to Masked Content who joined Neorx as Masked Content
Find 2 more new buyers
Company Profile Activity
Activity Insights
Neorx is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Neorx is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Neorx.
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Neorx
NeoRx is a cancer therapeutics development company. The Company's product pipeline includes STR(TM), a radiotherapeutic targeting bone, currently in a pivotal phase III clinical trial for patients with primary refractory multiple myeloma, and NX 473, a next-generation platinum therapy that the Company plans to evaluate in the treatment of patients... Read More
